Article

Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravis

2025-11-19

Abstract excerpt

Myasthenia gravis, an autoimmune disease characterized by muscle weakness that can manifest in bulbar dysfunction and respiratory distress, is driven in a subset of patients by autoantibodies against muscle-specific receptor tyrosine kinase (MuSK MG). MuSK MG and other autoantibody mediated disorders are generally treated with broad immunosuppressive approaches such as corticosteroids, plasmapheresis, B cell deple...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f9165b2-4c7e-5531-a3a4-a94db4131eab
DOI: 10.1101/2025.11.18.25340499

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravisDOI 10.1101/2025.11.18.25340499Read

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity Read

Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACsSemantic proximity Read

AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion <i>in vivo</i>Semantic proximity Read

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity Read

Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravisSemantic proximity Read

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravisSemantic proximity Read

Myasthenia gravis: from autoantibodies to therapy.Semantic proximity Read

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity Read

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravisSemantic proximity Read

B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravisSemantic proximity Read

Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.Semantic proximity Read

MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificitySemantic proximity Read